ORIC-101 not checked

ORIC Pharmaceuticals

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle”In the company’s words, NCT03928314 on ClinicalTrials.gov
Tested for
Solid Tumor, Prostatic Neoplasms
Main trialPhase 1
“The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.”In the company’s words, NCT03928314 on ClinicalTrials.gov

Other drugs for Solid Tumor

All 2439 drugs for Solid Tumor

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Terminated 22 Sep 2022 Study of ORIC-101 in Combination With Anticancer Therapy
Phase 1Terminated 22 Nov 2022 Study of ORIC-101 in Combination With Enzalutamide
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ORIC-101

Following is part of Solo: you see every change to ORIC-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in